US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

The investigators noted that the HYPERION trial had lost clinical equipoise based on robust evidence of clinical benefit from other trials. A phase 3 trial evaluating sotatercept-csrk (Winrevair ...

announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial ...

World Health Organization **Dr. McLaughlin is a member of the adult sotatercept steering committee, an investigator in the ZENITH and HYPERION trials and a paid consultant to Merck. The HYPERION ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

To that end, we are immensely proud to be able to present data from preclinical models that provide evidence of a synergistic treatment effect from the combination of seralutinib and sotatercept ...

Merck has high hopes for Winrevair to be among the portfolio of assets that will blossom as the company loses patent protection for cancer superstar Keytruda later this decade. Merck gained ...

Many people would rather take all the guesswork out of it and get a generally accommodating, safe pick, which is what you get with the Tuft & Needle Original mattress. It's a no-frills ...

Propranolol's protective effect was found to be more pronounced in women with migraines without aura and for ischemic stroke. For patients with migraine, the clinical benefits of propranolol, a ...